Article Information
History
- March 24, 2021.
Article Versions
- Version 1 (March 22, 2021 - 13:54).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- H. Christian Hong1,
- Kwang Sung Kim2,
- Shin Ae Park3,
- Min Jeong Chun1,
- Eun Young Hong5,
- Seung Won Chung1,
- Hyun Jong Kim4,
- Byeong Gyu Shin2,
- Abdennour Braka7,
- Jayaraman Thanappan7,
- Sunghoon Jang7,
- Sangwwok Wu7,8,
- Yang Je Cho6,* and
- Seok-Hyun Kim1,2,*
- 1EG-COVID Research Team, Research and Development Center, EyeGene Inc., 122-1 Uijang-Ro, Goyang-Shi, Gyeonggi-Do, 10551 Korea
- 2Research Laboratory, Research and Development Center, EyeGene Inc
- 3Immunology Research Team, Research and Development Center, EyeGene Inc
- 4R&D Strategy Team, Research and Development Center, EyeGene Inc
- 5In vivo Team, Research and Development Center, EyeGene Inc
- 6Chief Technology Officer, EyeGene Inc., Suite B-910, 401 Yangchun-Ro, Gangseo-Ku, Seoul 07528 Korea
- 7PharmCADD, Busan 48060, Korea
- 8Department of Physics, Pukyong National University, Busan 48513 Korea
- ↵*Corresponding authors: Yang Je Cho white{at}eyegene.co.kr and/or Seok-Hyun Kim burgundy{at}eyegene.co.kr